Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 2/20 | 0.38 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.37 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.37 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.36 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 4/20 | 0.34 |
| ▸ | PDE2A | O00408 | 3/20 | 0.34 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.34 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.34 |
| ▸ | CDK4 | P11802 | 1/20 | 0.33 |
| ▸ | CCND3 | P30281 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14028851 | 1.00 | KMO (0.38) | KMOHCRTR1HCRTR2MRGPRX4KDM4C | |
| SCHEMBL14028846 | 0.90 | KMO (0.40) | KMOHCRTR1HCRTR2MRGPRX4KDM4C | |
| SCHEMBL14028845 | 0.90 | KMO (0.40) | KMOHCRTR1HCRTR2MRGPRX4KDM4C | |
| SCHEMBL14541179 | 0.89 | KMO (0.35) | KMOHCRTR1HCRTR2CNR2FFAR2 | |
| SCHEMBL14028848 | 0.88 | KMO (0.39) | KMOMRGPRX4KDM4CCNR2MDM2 | |
| SCHEMBL14028847 | 0.88 | KMO (0.39) | KMOMRGPRX4KDM4CCNR2MDM2 | |
| SCHEMBL14028196 | 0.83 | KMO (0.43) | KMOCNR2CDK4CCND3GSK3B | |
| SCHEMBL14028388 | 0.83 | KMO (0.40) | KMOCNR2CDK4CCND3GSK3B | |
| SCHEMBL14541171 | 0.83 | KMO (0.38) | KMOCNR2CDK4CCND3GSK3B | |
| SCHEMBL14028207 | 0.82 | KMO (0.42) | KMOCNR2CDK4CCND3GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080279829-A1 | Phenyl-(4-Phenyl-Pyrimidin-2-Yl)-Amines For Enhancing Immunotolerance | WOISETSCHLAEGER MAXIMILIAN | 2008-11-13 | — | — | US | disclosed |
| WO-2007039216-A1 | PHENYL-(4-PHENYL-PYRIMIDIN-2-YL)-AMINES FOR ENHANCING IMMUNOTOLERANCE | NOVARTIS AG (CH) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080279829-A1 | Phenyl-(4-Phenyl-Pyrimidin-2-Yl)-Amines For Enhancing Immunotolerance | IFNG, IL2, LY96 | KMO 716/4885HCRTR1 2923/4885HCRTR2 2308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.